Isosorbide Dinitrate And Hydralazine Hydrochloride Tablet, Film Coated
Product Images NDC 72162-2343

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Isosorbide Dinitrate And Hydralazine Hydrochloride (NDC 72162-2343). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Isosorbide 01)

Chemical structure of isosorbide dinitrate, an active ingredient in isosorbide dinitrate and hydralazine hydrochloride tablets. The diagram depicts the molecular arrangement of atoms in the isosorbide dinitrate compound.*

FDA Label Image

Chemical Structure (Isosorbide 02)

Chemical structure diagram showing the molecular formula for hydralazine hydrochloride, part of the combination drug isosorbide dinitrate and hydralazine hydrochloride.*

FDA Label Image

Figure 1 (Isosorbide 03)

A Kaplan-Meier plot showing percent survival over time (in days) for black patients in a clinical trial. The plot compares survival between two groups labeled BiDil and Placebo, indicating a 43% reduction in mortality with BiDil. The graph includes a p-value of 0.012 from a log-rank test, with survival percentages ranging from 85 to 100 over approximately 600 days.*

FDA Label Image

Figure 2 (Isosorbide 04)

A Kaplan-Meier plot showing time to first hospitalization for heart failure in Black patients with A-HeFT. The graph compares the percentage without hospitalization over time (days) between BiDil and placebo groups, indicating a 39% risk reduction with BiDil and a p-value less than 0.001 by Log-Rank test.*

FDA Label Image

Figure 3 (Isosorbide 05)

A bar chart titled 'Change in Minnesota Living With Heart Failure Score' comparing BiDil and placebo groups over 3 to 18 months and at study endpoint. The vertical axis shows change in score with improvement downward. BiDil bars show greater improvement compared to placebo, with statistical significance markers at some time points. Sample sizes for BiDil and placebo groups at each time are listed beneath the graph.*

FDA Label Image

Figure 4 (Isosorbide 06)

A forest plot chart displaying results for demographic, baseline medication, and clinical characteristic subgroups in Black patients from the A-HeFT study. The chart shows relative risk and 95% confidence intervals comparing BiDil versus placebo for all-cause mortality and first hospitalization for heart failure, with subgroup categories including age, gender, ischemic and hypertensive heart failure etiology, history of hypertension, diabetes mellitus, chronic renal insufficiency, use of various medications, and systolic blood pressure status.*

FDA Label Image

Label (Lbl721622343)

Label for Isosorbide Dinitrate and Hydralazine HCl tablets showing strength of 20 mg/37.5 mg. The label indicates the product contains 90 film-coated tablets and is Rx only. It is relabeled by Bryant Ranch Prepack and manufactured by Lannett Company, Inc. Storage instructions and dosage reference are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.